Headache News and Research

Latest Headache News and Research

NS1 protein can be considered as vital target for development of new drugs to treat dengue: Study

Dengue is a mosquito-borne tropical disease currently endemic in more than 10 countries. According to the World Health Organization, 390 million people are infected by dengue every year.

7 Oct 2015

Calcitonin-gene related peptide antibody inhibition shows migraine prevention promise

TEV-48125, a monoclonal anti-calcitonin-gene related peptide antibody, is well tolerated and effective in the prevention of high-frequency episodic migraine and chronic migraine, findings from two phase IIb studies show.

2 Oct 2015

One-third of people living with diabetes fail to report night-time hypoglycaemia to their doctor, shows research

A new survey reports that one-third (32%) of people living with diabetes failed to report night-time hypoglycaemia to their doctor or nurse despite the impact they have on the lives of people living with the condition.

1 Oct 2015

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.

1 Oct 2015

Risks of water intoxication increase as outdoor endurance recreation grows in popularity

While emphasis is often placed on keeping athletes and outdoor enthusiasts properly hydrated, too much water can be just as dangerous. Exercise-associated hyponatremia (EAH), also known as water intoxication, results in an extreme, and potentially fatal, sodium imbalance.

30 Sep 2015

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

Teva Pharmaceutical Industries Ltd., has presented results from a post hoc analysis of two pivotal Phase III clinical trials showing that treatment with reslizumab reduced clinical asthma exacerbations (CAEs) by 75 percent versus placebo in a subgroup of patients with late onset asthma (diagnosed at 40 years of age and older) with elevated blood eosinophils, who were inadequately controlled on inhaled corticosteroids (ICS).

28 Sep 2015

New app may help athletes identify possible concussion symptoms

Sports-related concussions have sparked a national debate, multiple lawsuits and new concussion-management protocols in the NCAA and NFL in the last few years. Despite all the attention to concussion and its risks, many student-athletes either don't recognize the signs of concussion -- or won't report them if they do.

28 Sep 2015

Lumbar puncture well-accepted by memory clinic patients

Researchers support the increasing use of lumbar punctures (LPs) by memory clinics to collect cerebrospinal fluid, as long as certain risk factors are taken into account.

25 Sep 2015

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

AbbVie, a global biopharmaceutical company, today announced results from two Phase 2 clinical trials evaluating its investigational selective JAK1 inhibitor, ABT-494, in patients with inadequate response to either methotrexate or TNF inhibitors.

25 Sep 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

BioDelivery Sciences and Endo present Phase 2 data on buprenorphine HCl buccal film in patients with chronic pain

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, and BioDelivery Sciences International, Inc. today presented data from a Phase 2 study for the investigational drug buprenorphine HCl buccal film utilizing BDSI’s patented BioErodible MucoAdhesive (BEMA) drug delivery technology.

11 Sep 2015

Allergan settles patent litigation with Amneal related to NAMENDA XR extended release capsules

Allergan plc, today announced that its subsidiaries Forest Laboratories, LLC and Forest Laboratories Holdings, Ltd., along with Adamas Pharmaceuticals, Inc., have entered into a settlement agreement with Amneal Pharmaceuticals LLC and related companies and subsidiaries.

10 Sep 2015

Research provides better understanding of workday breaks, debunks common myths

Most people take breaks during their workdays. Coffee breaks. Lunch breaks. Short chats with coworkers. Maybe late afternoon walks around the building.

10 Sep 2015

Researchers discover potential biomarker for episodic migraine

Researchers may have discovered a new marker found in the blood for episodic migraine, according to a study published in the September 9, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

10 Sep 2015

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.

9 Sep 2015

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States.

9 Sep 2015

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics Inc., a subsidiary of Vernalis plc, today announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to adult patients and physicians in the United States.

8 Sep 2015

Acupuncture may be viable treatment for women experiencing hot flashes

Acupuncture may be a viable treatment for women experiencing hot flashes as a result of estrogen-targeting therapies to treat breast cancer, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania. Hot flashes are particularly severe and frequent in breast cancer survivors, but current FDA-approved remedies for these unpleasant episodes, such as hormone replacement therapies are off-limits to breast cancer survivors because they include estrogen.

4 Sep 2015

Acupuncture: A viable treatment for breast cancer survivors experiencing hot flashes

3 Sep 2015

Headache News and Research

Latest Headache News and Research

NS1 protein can be considered as vital target for development of new drugs to treat dengue: Study

Calcitonin-gene related peptide antibody inhibition shows migraine prevention promise

One-third of people living with diabetes fail to report night-time hypoglycaemia to their doctor, shows research

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

Risks of water intoxication increase as outdoor endurance recreation grows in popularity

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

New app may help athletes identify possible concussion symptoms

Lumbar puncture well-accepted by memory clinic patients

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

BioDelivery Sciences and Endo present Phase 2 data on buprenorphine HCl buccal film in patients with chronic pain

Allergan settles patent litigation with Amneal related to NAMENDA XR extended release capsules

Research provides better understanding of workday breaks, debunks common myths

Researchers discover potential biomarker for episodic migraine

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Acupuncture may be viable treatment for women experiencing hot flashes

Acupuncture: A viable treatment for breast cancer survivors experiencing hot flashes

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in